Columbia Laboratories Events Calendar

   Current Events Date Time
CBRX Q1 2014 Financial Results Conference Call  04/29/2014 8:30am EDT
           Toll-free U.S. - (877) 870-4263 
Canada - (855) 669-9657
           International: (412) 317-0790
          

Webcast:

click here

   Archived Events     Date Replay Until
   CBRX Q4 and YE 2014 Financial Results Conference Call

03/05/2014

05/05/2015

   CBRX presentation at the BIO CEO & Investor Conference

 02/11/2014

05/11/2014

   CBRX Q3 2013 Financial Results Conference Call

11/07/2013

11/07/2014

CBRX Q2 2013 Financial Results Conference Call

08/07/2013

08/07/2014

CBRX Q1 2013 Financial Results Conference Call

05/09/2013

05/09/2014

The previously-recorded webcasts included in this "Events" section are provided as a service to investors and other interested parties. They contain forward-looking statements, which statements are indicated by the words “may,” “will,” “plans,” “believes,” “expects,” “anticipates,” “potential,” “should,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Factors that might cause future results to differ include, but are not limited to, the following: Actavis' and Merck Serono's success in marketing CRINONE for use in infertility in their respective markets; changes in timing and quantity to Merck Serono's supply orders; timely and successful renewals by Merck Serono of the license for CRINONE in major ex-U.S. markets; Merck Serono's success gaining entry to new markets for CRINONE; the successful launch by Actavis of the next-generation vaginal progesterone product for the U.S. market;  our ongoing ability to retain current and attract new customers;  difficulties or delays in manufacturing; the availability and pricing of third-party sourced products and materials; successful compliance with FDA, MHRA, and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations; the ability to obtain and enforce patents and other intellectual property rights; the impact of patent expiration; the impact of competitive products and pricing; the cost of evaluating potential strategic transactions; our inability to maintain effective reporting internal controls over financial reporting; the strength of the United States dollar relative to international currencies, particularly the euro, the British pound and the Swiss franc; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the SEC. Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein.